Skip to main content

Table 2 Therapeutic peptides and their uses

From: Evaluation of the use of therapeutic peptides for cancer treatment

Peptide name

Validation

Cell lines examineda

Ref.

Antimicrobial peptides

 Magainin II

in vitro

Bladder cancer cells: RT4 pathologic grade 1, 647 V grade 2, and 486P grade 4

[32]

 NRC-3 and NRC-7

In vitro & in vivo

Breast cancer: MDA-MB-231, MDA-MB-468, SKBR3, MCF-7 and paclitaxel resistant MCF-7 (MCF-7-TX400) and murine mammary 4 T1 carcinoma cells

[34]

 Buforin IIb

In vitro & in vivo

Cervical carcinoma (HeLa), leukaemia (Jurkat cells) and lung cancer (NCI-H460) cells

[37]

 BR2

in vitro

Cervical carcinoma (HeLa), colon cancer (HCT116) and murine melanoma (B16-F10) cells

[52]

Cell penetrating peptides

 Dox-TAT

in vitro

Breast cancer (MCF-7 and MCF-7/ADR) and rat prostate carcinoma (AT3B1) cells

[53]

Tumour targeting peptides

 RGD-SSL-Dox

In vitro & in vivo

Melanoma (A375) and murine (B16-F10) melanoma cells

[61]

 LPD-PEG-NGR

In vitro & in vivo

Fibrosarcoma (HT-1080) cells

[66]

Therapeutic peptides target transduction pathway

 PNC-2 and PNC-7

in vitro

Pancreatic cancer (MIA-PaCa) cells

[109]

 Cardiac natriuretic peptides

In vitro & in vivo

Pancreatic cancer (HPAC), renal carcinoma (SW156), breast adenocarcinoma (HCCI428), ovarian adenocarcinoma (NIHOVCAR-3), modularly thyroid carcinoma (TT), glioblastoma (LNZTA3WT4) and lung carcinoma (NCI-H1963) cells

[111–118]

 RGD-PEG-Suc-PD0325901

In vitro & in vivo

Glioblastoma (U87MG) cells

[126]

 VWCS

In vitro

Head and neck squamous cell carcinoma (HNSCC) and oral epidermoid carcinoma (KB) cells

[140]

 FWCS

In vitro

Head and neck squamous cell carcinoma (HNSCC) and oral epidermoid carcinoma (KB) cells

[141]

Therapeutic peptides target cell cycle

 p16

In vitro

Pancreatic cancer (AsPC-1 and BxPC-3) cells

[166]

 Bac-7-ELP-p21

In vitro

Ovarian carcinoma (SKOV-3) cells

[75]

 Pen-ELP-p21

In vitro

Cervical carcinoma (HeLa) and ovarian carcinoma (SKOV-3) cells

 

Therapeutic peptides induce cell death

 TAT-Bim

In vitro & in vivo

Murine T-cell lymphoma (EL4), pancreatic cancer (Panc-02) and melanoma (B16-F10) cells

[193]

 Poropeptide-Bax

In vitro

Melanoma (SK-MEL-28) cells

[194]

 R8-Bax

In vitro & in vivo

Cervical carcinoma (HeLa) and murine mammary carcinoma (TS/A) cells

[194]

 CT20p-NP

In vitro & in vivo

Breast cancer (MCF-7 or MDA-MB-231) and colon cancer (HCT-116) cells

[195]

 RRM-MV

In vitro

Squamous cell carcinoma (COLO16) and malignant melanoma (MM96L), and murine melanoma (B16-F10) cells

[197, 199]

 RRM-IL12

In vitro

Mouse melanoma (B16-F10) cells

[197]

Therapeutic peptides target tumour suppressor protein

 PNC-27

In vitro

Cervical carcinoma (HeLa), colon cancer (SW1417 and H11299), breast cancer (MDA-MB-453 and MCF-7), osteosarcoma (SAOS2), leukaemia (K562), pancreatic cancer (MIA-PaCa-2) and melanoma (A-2058) cells. Rat k-ras-transformed pancreatic cancer (TUC-3) and transformed endothelial (E49) cells

[214, 216, 217]

 PNC-21

In vitro

Cervical carcinoma (HeLa), colon cancer (SW1417 and H1299), breast cancer (MDA-MB-453), and osteosarcoma (SAOS2) cells. Rat k-ras-transformed pancreatic cancer (TUC-3) and transformed endothelial (E49) cells

[214]

 PNC-28

In vitro & in vivo

Breast cancer (MDA-MB-453), colon cancer (H1299 and SW1417), osteosarcoma (SAOS2), cervical carcinoma (HeLa) and pancreatic cancer (MiaPaCa-2) cells. Rat k-ras-transformed pancreatic cancer (TUC-3) and transformed endothelial (E49) cells

[214, 219, 232]

 Tat-αHDM2

In vitro & In vivo

Melanoma (MM-23, MM-24 and MM-26), retinoblastoma (Y79 and WERI), osteosarcoma (U2OS), and cervical carcinoma (C33A) cells

[220]

Therapeutic peptides target transcription factors

 Int-H1-S6A, F8A

In vitro

Breast cancer (MCF-7) cells

[230]

 Pen-ELP-H1

In vitro

Breast cancer (MCF-7) cells

[76]

 BACl-ELP-H1

In vivo

Glioma (U-87 MG and D54) and murine glioma (C6) cells

[231]

  1. aUnless specified otherwise, all cell lines are human in origin